. Verification: 8ea7dd8e8067cf6e

Well, folks, it seems like we've stumbled upon the age-old question of whether the pursuit of endless COVID vaccines is our new national pastime. With Big Pharma churning out jabs faster than you can say "side effects," one can't help but wonder if they've found the golden goose. Will we ever break free from this vaccine merry-go-round, or are we destined to spend our lives in an eternal game of pharmaceutical whack-a-mole? Only time will tell, but hey, at least we're keeping the needle industry in business, right?

Up until now, the general sentiment towards the latest advancements in COVID-19 vaccines, namely those developed by Pfizer and Moderna, which recently garnered approval and emergency use authorization from the Food and Drug Administration (FDA), has been predominantly unfavorable. This negative response is not without merit, given the untested and unverified nature of these shots.

Astoundingly, Newsweek, a publication that had once advocated for the incarceration of the unvaccinated just a few years ago, is now criticizing the FDA for greenlighting these novel "vaccines" without subjecting them to any human clinical trials.

As reported, these fresh "booster" doses, or whatever nomenclature one chooses to apply, underwent evaluations solely on a minuscule sample size of mice – a mere eight of them. If this doesn't exemplify subpar scientific rigor, then it's unclear what does.

Newsweek's Nick Mordowanec highlights the contentious issue: "These updated boosters will be the first to reach the public without undergoing any form of clinical trials involving humans, a fact that has raised concerns among certain quarters regarding their efficacy."

In recent months, the push for additional COVID vaccinations has been a hot topic of debate, with the FDA playing a pivotal role in encouraging Pfizer and Moderna to develop new vaccines. Back in June, the FDA expressed concerns about the emergence of a potential fall season variant of COVID that might not be effectively covered by the existing vaccines, prompting the call for new vaccine development.

Mandy Cohen, the director of the U.S. Centers for Disease Control and Prevention (CDC), spoke about the significance of these new vaccines, noting, "We now possess an array of tools to mitigate the severe consequences of COVID-19." Cohen acknowledges that, similar to other coronaviruses like the common cold, COVID is likely here to stay. However, she questions the feasibility of simply adapting to its presence when there's a profitable alternative.

In an op-ed for The New York Times, Cohen argues that the only way to combat serious illnesses, hospitalizations, and deaths caused by each new COVID variant is to continually develop and administer updated vaccines. She argues, "COVID has the ability to evade our immune defenses by constantly evolving. Therefore, our vaccines must be modified to match these changes. Even though many Americans have previously been infected with earlier virus strains, their immunity diminishes over time."

FDA Commissioner Dr. Robert Califf, in an August 25th statement, highlighted that the FDA expedited the approval process for the latest vaccines by relying on clinical trial data from previously approved mRNA COVID boosters instead of conducting new human clinical trials. He also pointed out that adjusting vaccines to include different virus strains is a standard practice, citing the annual flu vaccine as an example.

The public's willingness to receive these vaccines remains uncertain, with some hospital systems contemplating mandates as a way to encourage vaccination. As long as the FDA continues to grant approvals and emergency use authorizations for these vaccines, it appears that the cycle of new vaccine development will persist, raising concerns among those skeptical of the long-term consequences.

We need your help to continue to post news that matters...You can support our efforts by buying us a coffee... It’s quick, secure, and easy. https://gogetfunding.com/realnewscast/